Sec. 8. If: (1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing amygdalin (laetrile) to be used within the facility; and (2) providing or allowing use of amygdalin (laetrile) within the facility would jeopardize the receipt of: (A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or (B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t); the hospital or other health care facility may prohibit the use of amygdalin (laetrile) within the hospital or facility. [Pre-1993 Recodification Citation: 16-8-8-7(b).] IC 16-42-24 Chapter 24. Drugs: Use of Chymopapain 16-42-24-1 Record of use 16-42-24-2 Administration restricted 16-42-24-3 Hospital's restricting or forbidding use prohibited; conditions 16-42-24-4 Disciplinary action against attending physician prohibited if use requested by patient 16-42-24-5 Use permitted in place of other therapies if requested by patient 16-42-24-6 Construction of chapter 16-42-24-7 Use request form 16-42-24-8 Regulation of manufacture, distribution, sale, or use 16-42-24-9 Manufacture, sale, distribution, or prescription not required 16-42-24-10 Use prohibition by health care facility facing loss of federal funding
‹ Prev All Indiana sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.